CTLA4 and colitis: Noteworthy, the Bacillota phylum that elicited Ig responses in the study cohort, was enriched in the baseline fecal microbiota of metastatic melanoma patients, who benefited from the anti-CTLA-4 therapy and more frequently experienced treatment-induced colitis [44].